Definition and management of invasive fungal rhinosinusitis: a single-centre retrospective study
Objectives. The purpose of this study was to correlate acute invasive fungal rhinosinusitis (AIFRS) and chronic invasive fungal rhinosinusitis with underlying diseases, aetiological microorganisms, clinical symptoms, radiological findings, and surgical and medical treatment to determine the subset of patients who require more accurate diagnostic investigation and to prevent irreversible complications. Methods. This retrospective monocentric study included 17 patients who underwent endoscopic sinus surgery evaluated by paranasal computed tomography and magnetic resonance imaging. Age, sex and symptoms, and location of the invasive fungal infection and the causative fungus were analysed. Results. In total, 4 patients were affected by the AIFRS form, and 13 by the chronic form. Diabetes mellitus was reported in 41.17% of cases, and haematological diseases in 23.52%. The maxillary sinuses were involved in 47.05% of cases and sphenoidal sinuses in 52.94%; Aspergillus fumigatus was the fungus in 76.47% of cases, and Zygomycetes in 23.53%. Conclusions. An understanding of the different types of fungal sinusitis and knowledge of their features play a crucial role in reaching prompt diagnosis and initiation of appropriate therapy, which is essential to avoid a protracted or fatal outcome.
The concept of invasiveness for a fungal infection refers to the potential for fungal hyphae to invade epithelial tissue with potential neural and vascular involvement 1,2. We can categorise invasive fungal rhinosinusitis (IFRS) into three subgroups: acute invasive fungal rhinosinusitis (AIFRS), chronic invasive fungal rhinosinusitis and chronic granulomatous invasive fungal rhinosinusitis 3.
Invasive fungal rhinosinusitis (IFRS) generally occurs in immunocompromised patients, i.e. those with haematological malignancies or undergoing chemotherapy or allogeneic haematopoietic transplantation, patients with AIDS, and in poorly controlled diabetic patients undergoing immunosuppressive therapy 4.
Acute invasive fungal rhinosinusitis (AIFRS) is defined by a time course of less than 4 weeks’ duration, with predominant vascular invasion. The infection results from rapid spread of fungi from the paranasal sinuses to the adjacent orbits and central nervous system with hyphal invasion of blood vessels, vasculitis with thrombosis, haemorrhage, tissue infarction and acute neutrophilic infiltrates with a necrotising pathological reaction 5.
Despite improvements in both medical and surgical therapies, the mortality of patients with IFRS remains high (50-80%) mostly due to invasion of the orbit and intracranial cavity 8,9; in fact, early and accurate diagnosis is essential because prognosis is often governed by the rapid initiation of antifungal therapy and/or surgical debridement 10.
Therefore, the purpose of this article was to correlate AIFRS and chronic indolent IFRS with underlying diseases, aetiological microorganisms, clinical symptoms, radiological findings, and surgical and medical treatment.
The study aimed to aid clinicians in the decision-making process by systematically assembling previously published evidence and new updates on medical treatment, and to consider the possibility of identifying a subset of patients who require more accurate diagnostic investigation to prevent irreversible complications.
Materials and methods
This single-centre retrospective study included 17 patients affected by IFRS who underwent endoscopic sinus surgery (ESS) at the ENT Department in San Luigi Gonzaga Hospital, Turin, Italy between January 2016 and January 2020.
For inclusion, patients were required to have histopathologically confirmed IFRS, defined by the evidence of fungal hyphae in the mucosa of the affected sinus. Patients aged < 18 years, those who had previously received nasal surgery or who had been diagnosed with non-invasive fungal rhinosinusitis were excluded.
Patients’ records were analysed retrospectively for presenting symptoms, underlying diseases, causative microorganisms, radiological findings, and medical and surgical treatment. All enrolled patients were evaluated preoperatively with paranasal computed tomography (CT) and magnetic resonance imaging (MRI). In addition, age, sex and symptoms as well as the location of the invasive fungal infection and the causative fungus were analysed for each patient.
Tissue samples were collected for both microbiological and histopathological examination to provide a definitive diagnosis. A mucosal biopsy sample was also collected from the sinus wall and evaluated histologically. A swab sample was taken from purulent sinus secretions and sent to the microbiology laboratory for bacterial culture under both aerobic and anaerobic conditions. When feasible, galactomannan and beta-D-glucan were tested in blood samples. Galactomannan (GM) is a molecule that is present in the cellular walls of Aspergillus species and can be secreted extracellularly. Several studies have shown that the determination of GM is beneficial for diagnosis and, together with 1,3-beta-D-glucan (BDG) antigens, can improve the sensitivity of invasive aspergillosis diagnosis 11.
All patients underwent debridement through endoscopic sinus surgery (ESS) under general anaesthesia as the first choice to remove the entire lesion in the sinus using rigid endoscopes (Karl Storz Endoskope, Germany) with a diameter of 4 mm and viewing angles of 0°, 45° and 70°. After surgery, specific medical antifungal treatment was initiated as prescribed by an infectious disease specialist, and in the case of positive cultures indicating bacterial coinfection, the type of antibiotic therapy was determined by antibiogram results. All patients were prospectively followed through endoscopic monitoring performed at intervals of 15, 30, 60, 90 days, 6 months and 1 year after surgery. Using a rigid endoscope, secretions and crusts were removed at the outpatient department and postoperative home treatment included nasal saline irrigation twice a day for at least 3 months. Therapeutic success was clinically and endoscopically defined as patients who were asymptomatic at 6 months after completing the antifungal therapy. Follow-up with MRI was only performed when recurrence was suspected. No patient was lost during the follow-up period. This study was in line with the guidelines of the Helsinki Declaration for ethical consideration. Accordingly, written informed consent was obtained from all patients. Categorical data are presented as frequencies.
The study included 17 patients (8 women and 9 men) affected by IFRS, diagnosed between January 2016 and January 2020. Their median age was 57 years, range: 31-82 years, and the interquartile range (IQR) was 27 ± 14.77 years. In total, 4 patients were affected by the AIFRS form (Tab. I) and 13 patients had the chronic indolent form (Tab. II).
The most common underlying disease was diabetes mellitus reported in 7 cases (41.17%) followed by haematological diseases in 4 cases (23.52%): myelodysplastic syndrome (n = 1), non-Hodgkin lymphoma (n = 1) and acute myeloid leukaemia (n = 2). Furthermore, 5 patients (29.41%) had neutropenia. An autoimmune condition, rheumatoid arthritis, was recognised in 1 case. Another cause of immunodeficiency was steroid therapy, found in 1 patient. Alveolar rhabdomyosarcoma together with chemoradiotherapy and neutropenia were observed in 1 patient. As reported in Tables I and II, several patients showed different associations of these underlying diseases, with different symptoms occurring simultaneously in the same patient.
Facial pain and headache were the most commonly reported presenting signs and symptoms in 12 (70.58%) and 8 (47.05%) patients, respectively; 6 patients had ocular diseases (35.29%): diplopia was observed in 4 patients (23.52%), proptosis in 3 (17.64%) and bilateral amaurosis in 1 case (5.88%). Cranial nerve palsy (VI) was present in 2 patients (11.76%) and trigeminal neuralgia in 1 patient (5.88%). The average time between the onset of symptoms to presentation in the emergency room and the beginning of the diagnostic process was about 2 days for AIFRS and 10 days for the chronic indolent form. No patient had received medical treatment at other healthcare facilities.
CT and MRI were used preoperatively to determine the extent of fungal invasion: 14 (82.35%) patients had unilateral involvement of the paranasal sinuses and one of them (5.88%) also showed the simultaneous involvement of two different sinuses, the maxillary and sphenoid sinus (#4 Tab. II) on the right side. Three patients (17.64%) had bilateral fungal invasion.
Our data also showed involvement of the maxillary sinuses in 8 patients (47.05%) and of the sphenoid sinuses in 9 patients (52.94%); there was simultaneous involvement of both paranasal sinuses in 1 patient (5.88%). The principal radiologic findings with CT and MRI are summarised in Tables III and IV, respectively.
Five patients showed extra-sinus involvement of the fungal disease (29.41%): the cavernous sinus was the site of the most frequent dissemination being present in 5 patients (29.41%), followed by 2 cases (11.76%) with intracranial involvement and 2 cases (11.76%) with thrombosis of the internal carotid artery (ICA) (11.76%). Ocular manifestations were also detected: orbital and optic nerve involvement (n = 2, 11.76%) and VI cranial nerve palsy (n = 4, 23.52%).
All patients underwent endoscopic debridement with endoscopic sinus surgery (ESS) under general anaesthesia, with complete removal of all necrotic tissue. No other surgical procedures were performed. The time from the patient’s arrival at the hospital to ESS varied from less than 1 day to 70 days (median: 35 days, IQR: 57.5 days): all AIFRS patients underwent emergency ESS immediately. In the group with the chronic indolent form, the delay to surgery in 1 patient (#13) was linked to the onset of concomitant diseases which required further investigations by other specialists and, consequently, postponed the anaesthesiologic eligibility for surgery.
Bilateral nasal packing was performed in each patient and was removed 48 hours after surgery. No intraoperative complications occurred (Figs. 1-3).
Histological examination confirmed the invasive fungal disease in all cases: Aspergillus was detected in 13 patients (76.47%) (1 patient in the AIFRS group and 12 patients in the group with the chronic form), and Zygomycetes was detected in 4 patients (23.52%): the intraoperative view showed typical friable cheesy-like yellow to brown material in sinus cavities, confirming the fungal aetiology of the disease already diagnosed macroscopically.
Microbiological analysis was also performed: Aspergillus fumigatus was isolated in 7 patients (41.17%), Rhizomucor in 1 (5.88%), and Penicillium in 1 case (5.88%). The causative microorganism could not be determined in 8 patients (47.05%).
Bacterial co-infections occurred in 6 patients (35.29%) and were most frequently caused by Staphylococcus species and Pseudomonas aeruginosa (11.76%), followed by one case of Streptococcus pyogenes (5.88%), one case of Actinomyces (5.88%) and one of Haemofilus influenzae (5.88%).
All patients promptly started systemic antimycotic treatment. Voriconazole was administered to 13 patients (76.47%); the 200 mg bid intravenous formulation was preferred initially and was switched to an oral formulation when possible, on average after a period of 3.41 months (range = 20 days-12 months, median = 2 months, IQR = 2); 4 patients (23.52%) were treated with liposomal amphotericin B (L-AmB) (range = 3 days-12 months, median = 0.74 months, IQR = 1.88) with dosages from 3 to 10 mg/kg/day; in 3 selected cases, isavuconazole with a dosage of 200 mg/day in intravenous or oral formulation or posaconazole at 300 mg/day were also used in association.
In total, 15 patients are still in follow-up with a mean duration of 20.12 months (range = 0.06-58 months; median = 16 months, IQR = 24), 2 patients died (11.76%), 1 patient from cerebral ischaemia and the other from uncontrolled rhinocerebral infection.
Only one relapse was observed with persistence of fungal pathology in the sphenoidal sinus, requiring revision surgery at 6 months and with a histological diagnosis of Aspergillus.
A diagnosis of IFRS requires histopathologic evidence of fungi invading nasal tissue, characterised by a dense accumulation of hyphae, the occasional presence of vascular invasion and a diffuse inflammatory reaction 12.
Acute IFRS is characterised by a rapid evolution and is associated with a high mortality rate that can reach 100% in cases of intracranial mycotic dissemination: Zygomycetes (Rhizopus, Mucor, Rhizomucor) and species of Aspergillus are the most common aetiologic agents in the sinonasal cavity, with more frequent neurovascular and orbital invasion 13.
CT scans show homogeneous opacification of the sinus with calcification, adjacent bone erosion, dehiscence of the lateral sphenoid’s recess with signs of remodeling in the wall of the sphenoid sinus, especially in immunocompromised patients 14. Signal intensity was evaluated using MRI, and was grouped into three categories: slightly T1-weighted iso- or hypointense, markedly T2-weighted hypointense (near signal void), and peripheral enhancement of the surrounding mucosa. On MRI, orbital and intracranial involvement were present as suggested findings, together with perineural spread and expansion outside the confines of the sinonasal cavity with cavernous sinus involvement or thrombosis of the ICA, and have been reported previously 15.
Clinical suspicion of AIFRS should be raised in the immunocompromised patient presenting with new-onset, rapidly progressive sinusitis or facial discomfort 16.
In our experience, symptomatology in AIFRS patients was very evident when a sphenoidal localisation was present (proptosis, diplopia, cranial nerve palsy (VI), trigeminal neuralgia, or visual abnormalities) because of a connection between the sphenoidal sinus and anatomic structures such as the ICA, cavernous sinus, optic nerve, eyehole, or brain 17. Therefore, thanks to the rapidity of onset, patients with AIFRS came immediately to our clinic, and we performed an emergency surgical intervention thereby preventing serious cerebral and ocular complications. On the other hand, patients with the chronic indolent form showed nonspecific and slowly progressive signs and symptoms that did not arouse suspicion in the patient, delaying access to the emergency room and consequently, to the diagnostic and therapeutic process.
As reported in a review of over 800 patients by Turner et al., Aspergillus spp. and Mucor spp. can both be found in neutropenic patients and in those with chronic systemic steroid treatment, whereas Mucor spp. has a propensity for diabetic and iron-overloaded patients 18.
Neutropenia plays a key role as a factor contributing to the development of infection in patients with haematological disease. In the present study, 29.41% of patients were affected by a severe neutropenic state, defined as a neutrophil count < 500/mmc 19, and 23.52% of patients had an underlying haematological disease, such as non-Hodgkin lymphoma, myelodysplastic syndrome or acute myeloid leukemia. Other underlying conditions included poorly controlled DM, immunosuppressive treatment and corticosteroid exposure 20.
Our data show a significant proportion of patients infected by Aspergillus fumigatus in the chronic indolent group (92.30%) and only one patient was affected (pt#1) by Zygomycetes (7.70%). Conversely, in AIFRS patients, Zygomycetes were the fungi mainly responsible for the infection and only in one patient (#2) was Aspergillus fumigatus isolated.
In line with the results obtained in our previous study 21, it is still unclear why the microbiological evidence for fungal disease was negative in 8 cases, although the radiologic and endoscopic intraoperative findings were strongly indicative of IFRS.
Treatment for both groups was based on a combination of antifungal therapy, reversal of immunocompromising factors, surgical debridement through ESS when possible and obtaining material for histopathological and cultural examinations 22.
Vaughan et al. analysed 37 mucormycosis cases and found no significant difference in survival between patients having surgery 1-30 days after diagnosis 23. These data agree with our study, with an onset of treatment on average 32.41 days after diagnosis, highlighting why the start of treatment should be initiated as soon as IFRS is diagnosed.
For an early surgical approach, the correct medical therapy must be promptly selected based on the fungal pathogen affecting the patient: we can generalise that the current mainstay of therapy for IFRS is L-AmB (recommended dosage from 3 to 10 mg/kg per day) 24. For invasive aspergillosis, treatment with voriconazole is recommended primarily for patients with cranial nerve involvement. Alternatively, isavuconazole, a second generation triazole, has been shown to be as effective as voriconazole and better tolerated. For mucormycosis IFRS treatment, L-AmB and posaconazole are the most recommended drugs, together with isavuconazole which can be administered in patients in whom amphotericin B cannot be administered because of intolerance or in the case of kidney disease. Combination therapy with two drugs has been reported. In the current study, 76.47% of our patients were treated with voriconazole, showing fewer systemic side effects than L-AmB, a favourable bone penetration and good tolerance as maintenance therapy.
Isavuconazole is an innovative and effective therapeutic option with a very high oral bioavailability (98%), a good profile of tolerability and efficacy and a low risk of interactions with other drugs 25. However, further studies are needed to better integrate isavuconazole in the management of patients with IFRS, with the aim to define a clear correlation between plasma levels and efficacy end points and to identify the best therapeutic window in which to administer it.
Due to the relative rarity of AIFRS, our data was limited to acute and chronic indolent IFRS, and unfortunately did not include granulomatous forms, thus precluding larger cohort studies. The results are dependent on the quality of the limited data available, but are in line with the current literature. Moreover, our study focused on differentiating acute and chronic indolent forms, which was not always easy to recognise with certainty in previous studies, so as to guide the most appropriate diagnostic and therapeutic process.
Invasive fungal rhinosinusitis is a difficult infection to diagnose and treat. Early diagnosis is the key to managing IFRS successfully, and with a systematic approach, it is possible to improve survival, taking into account the context of the temporal course of the diagnostic work-up and treatment. The goal is diagnosis of the disease at an earlier stage while it is confined to the sinonasal cavities before mucosal dissemination. A multidisciplinary approach consisting of antifungal therapy, surgical debridement, and reversal of predisposing conditions is the best therapy to improve survival.
Figures and tables
|ID sex, age||Underlying diseases||Presenting symptoms and signs||Sinuses involved||Extra sinonasal sites||Fungal species||Microbiologic||Antifungal therapy||F/U|
|1 M, 57||Acute myeloid leukaemia, Neutropenia||Diplopia cranial nerve palsy (VI), trigeminal neuralgia||SS (r)||Cavernous sinus thrombosis ICA, cerebral fungal infection||Zygo||Rhizomucor||L-AmB (74 d) ISC (12 m)||25 m|
|2 F, 56||Myelodysplastic syndrome Neutropenia||Facial pain proptosis||MS (r)||−||Asper||Asp. fumigatus||Vorico (12 m)||23 m|
|3 F, 53||Non-Hodgkin lymphoma Neutropenia||Diplopia, headache, proptosis, cranial nerve palsy (VI)||SS (r)||Cavernous sinus, VI cranial nerve, thrombosis ICA||Zygo||Neg.||L-AmB (15 d) ISC (9 m)||13 m|
|4 M, 76||Diabetes mellitus Debilitated||Headache amaurosis bilateral||SS (b)||Cavernous sinus, intracranial involvement, Optic nerve, Orbit||Zygo||Asp. fumigatus||L-AmB (3 d)||2 d/D|
|ID sex, age||Underlying diseases||Presenting symptoms and signs||Sinuses involved||Extra sinonasal sites||Fungal species||Microbiologic||Antifungal therapy||F/U|
|1 F, 52||Acute myeloid leukaemia Neutropenia||Facial pain||MS (b)||−||Zygo||Neg.||Vorico (1 m)||52 m|
|2 M, 65||Diabetes mellitus||Headache||SS (l)||−||Asper||Penicillium||Vorico (2 m)||49 m|
|3 F, 31||Alveolar rhabdomyosarcoma CHT+RT. N||Facial pain||MS (l)||−||Asper||Neg.||Vorico (2 m)||44 m|
|4 F, 43||Diabetes mellitus||Headache Facial pain||SS + MS (r)||−||Asper||Asp. fumigatus||Vorico (2 m)||40 m|
|5 M, 47||−||Facial pain||MS (r)||−||Asper||Asp. fumigatus||Vorico (1 m)||33 m|
|6 M, 47||Diabetes mellitus||Facial pain||MS (l)||−||Asper||Asp. fumigatus||Vorico (3 m)||29 m|
|7 M, 82||Steroid therapy||Headache, facial pain, diplopia||SS (r)||Cavernous sinus, intracranial involvement V3, Orbit||Asper||Neg.||Vorico (12 m)||16 m/D|
|8 M, 77||−||Facial pain||MS (l)||−||Asper||Neg.||Vorico (1 m)||14 m|
|9 F, 59||Diabetes mellitus||Facial pain||MS (l)||−||Asper||Neg.||Vorico (20 d)||14 m|
|10 F, 53||Rheumatoid arthritis||Headache facial pain||SS (b)||−||Asper||Neg.||Vorico (3 m)||13 m|
|11 M, 68||Diabetes mellitus||Facial pain||MS (r)||−||Asper||Neg.||Vorico (3 m)||12 m|
|12 F, 79||Diabetes mellitus||Headache Facial pain Proptosis, diplopia||SS (l)||Cavernous sinus||Asper||Asp. fumigatus||L-AmB (1 m), Posa (2 m)||8 m|
|13 M, 79||−||Headache||SS (l)||−||Asper||Asp. fumigatus||Vorico (3m)||4 m|
|Sinus involved||Calcification||Bony sclerosis||Bone erosion|
|MS||10 (58.8)||3 (17.6)||3 (17.6)|
|SS||5 (29.4)||6 (35.3)||4 (23.5)|
|Total n (%)||15/17 (88.2%)||9/17 (52.9%)||7/17 (41.1%)|
|Signal intensity||Extra-sinonasal involvement|
|Sinus involved||T1WI iso/ hypointense||T2 WI markedly hypointense||Peripheral enhancement||Cavernous sinus||Intracranial||Perineural spread||Orbital||Thrombosis ICA|
|MS||7 (41.1)||7 (41.1)||2 (11.7)||-||-||-||-||-|
|SS||9 (52.9)||9 (52.9)||3 (17.7)||5 (29.4)||2 (11.7)||4||2 (11.7)||2 (11.7)|
|Total n (%)||16/17 (94%)||16/17 (94%)||5/17 (29.4%)||5/17 (29.4%)||2/17 (11.7%)||4/17 (23.5%)||2/17 (11.7%)||2/17 (11.7%)|